Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Brain 7T MRI Findings in Patients with Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD)
Autoimmune Neurology
P9 - Poster Session 9 (8:00 AM-9:00 AM)
14-005
This study aimed to employ a 7T MRI of the brain to assess the central vein sign (CVS), leptomeningeal enhancement, and cortical lesions in people with MOGAD.

Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is an autoimmune-mediated inflammatory disorder of the CNS. Current data on advanced imaging biomarkers for MOGAD are limited.

MOGAD cases from Massachusetts General Hospital and Brigham and Women’s Hospital who met the international MOGAD criteria underwent 7T MRI (Siemens Magnetom Terra) using 3D MP2RAGE and 3D T2 FLAIR sequences with 0.7 mm^3 isotropic voxels. All patients were in remission with a minimum of 90 days since the last relapse at the time of the 7T MRI. Neuroimaging experts identified the presence of the central vein sign with white matter lesions, leptomeningeal enhancement, and cortical lesions.

We studied 11 individuals with MOGAD, 82% of whom were female, with a mean (SD) age of 43.3 (10.8) years at the time of MRI. All patients identified as Caucasian non-Hispanic. The median (IQR) MOG-IgG titer was 1:40 (1:40,1:1000). Ten out of 11 patients were receiving immunotherapy: IVIG (n=6), anti-CD20 (n=2), mycophenolate mofetil (n=1), or tocilizumab (n=1). Leptomeningeal enhancement was detected in 6 (54.5%) patients with a median (IQR) number of foci of 1 (0-3). Cortical lesions were found in 5 (45.4%) patients with a median (IQR) number of foci of 0 (0-1). A total of 21 T2 FLAIR hyperintense white matter lesions were identified, with 4 (19%) lesions being CVS-positive. There was no abnormal parenchymal enhancement of white matter lesions or cortical lesions.

7T MRI provides new information regarding potential pathologic features in MOGAD.
Authors/Disclosures
Michael Levy, MD, PhD, FAAN (Massachusetts General Hospital/Harvard Medical School)
PRESENTER
Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Pharma. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Levy has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various law firms. The institution of Dr. Levy has received research support from National Institutes Health.
Negar Molazadeh, MD (Brigham and Women's Hospital) The institution of Dr. Molazadeh has received research support from Genentech, Inc..
Jonathan D. Zurawski, MD (Brigham & Women's Hospital) The institution of Dr. Zurawski has received research support from The Race to Erase MS Foundation. The institution of Dr. Zurawski has received research support from Novartis Pharmaceuticals. The institution of Dr. Zurawski has received research support from I-Mab Biopharma . The institution of Dr. Zurawski has received research support from Elizabeth A. Kremer MS Research Foundation. The institution of Dr. Zurawski has received research support from Novartis.
Marcelo Matiello, MD, FAAN (Massachusetts General Hospital, Brigham, Harvard) Dr. Matiello has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Matiello has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion.
Shahamat Tauhid, MD (Brigham & Women's Hospital) Dr. Tauhid has nothing to disclose.
Tanuja Chitnis, MD, FAAN (Brigham and Women's Hospital) Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Chitnis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche-Genentech. Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Siemens. Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Academic CME. The institution of Dr. Chitnis has received research support from Novartis. The institution of Dr. Chitnis has received research support from Sanofi. The institution of Dr. Chitnis has received research support from Octave. The institution of Dr. Chitnis has received research support from Genentech-Roche.
Rohit Bakshi, MD, FAAN Dr. Bakshi has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. The institution of Dr. Bakshi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Neuroimaging. An immediate family member of Dr. Bakshi has received stock or an ownership interest from Biogen. The institution of Dr. Bakshi has received research support from BMS/Celgene. The institution of Dr. Bakshi has received research support from EMD Serono.